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PART ONE 
  
INTRODUCTION 
Glaucoma is a symptom complex which is chronic progressive in 
nature, characterised by the optic nerve head changes, with 
corresponding  changes in the visual field, with or without intraocular 
pressure as a modifiable  risk factor. 
Glaucoma is one of the leading causes of blindness throughout  
the world and its clinical evaluation  and management remains a 
challenge even today. World health organisation statistics indicate that 
glaucoma accounts for blindness in 5.1 million persons or 13.5% of 
global blindness.     
Glaucoma has been called as the "silent thief of sight" because the 
loss of vision normally occurs  slowly over a long period of time and is 
often only recognized when the disease is quite advanced. Once lost, 
this damaged visual field cannot be recovered. Worldwide, it is the 
second leading cause of blindness. It is also the leading cause of 
blindness among African Americans.  
Glaucoma affects 1 in 200 people aged fifty and younger, and 1 in 
10 over the age of eighty. If the condition is detected early enough ,it is 
possible to arrest the development or slow the progression with medical 
and surgical means. 
The word glaucoma comes from the Greek γλαύκωμα, "opacity of 
the crystalline lens”.  
Glaucomas are classified into primary & secondary forms.the 
most common form is primary open angle glaucoma,characterised by 
intraocular pressure>21 mm of Hg in atleast one eye,open and normal 
appearing  anterior chamber angle and glaucomatous  visual field loss or 
optic nerve head damage. 
  
HISTORICAL REVIEW 
The  HIPPOCRATIC   term “glaucosis” refer  to bluish  green hue 
of the affected eye, which included a large group of blinding disorders 
like cataract. It was not until the nineteenth century that glaucoma was 
recognised as a distinct group of ocular disorders. 
RICHARD BANNISTER  first discovered glaucoma in 1622 and 
differentiated between absolute glaucoma and cataract. 
VON GRAEFE  in the year  1857 first recognised optic nerve 
head  abnormality with disturbance of vision. 
In 1976, J.LAWTON SMITH  suggested the theory of 
glaucomatous disc changes and field changes in an eye with a tension of 
21mm of Hg                           
  
ANATOMY OF ANGLE OF ANTERIOR CHAMBER 
Angle of the anterior chamber is bounded at anterior side by the 
peripheral part of the cornea, trabecular meshwork, anterior face of the 
ciliary body and posterior wall is formed by the iris. The sclera groove 
lies between the sclera spur and anterior border ring of schwalbe’s line 
anteriorly which is occupied by the canal of schlemm and trabecular 
meshwork. 
TRABECULAR MESHWORK 
It is a triangular structure, the apex of which blends with the 
termination of descement’s membrane and deep corneal lamellae. The 
base of the triangle is attached to the anterior surface of sclera spur, 
anterior surface of ciliary body and root of the iris. The scleral sulcus is 
converted into a circular channel called schlemm’s canal by the 
trabecular  meshwork anterior part of meshwork is non-filtering and the 
posterior  filtering part is divided into 3 portions 
1. UVEAL MESHWORK 
2. CORNEO SCLERAL MESHWORK 
3. JUXTA CANALICULAR TISSUE 
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                        OPTIC NERVE HEAD 
The optic disc or optic nerve head is the location where ganglion 
cell axons exit the eye to form the optic nerve. There are no light 
sensitive rods or cones to respond to a light stimulus at this point. This 
causes a break in the visual field called "the blind spot" or the 
"physiological blind spot".  
At the surface of the nerve head, axons bend acutely to  leave the 
globe through a fenestrated sclera canal called the lamina cribrosa. 
Intraocular portion of the  optic nerve head has a diameter –1.5mm. 
Divisions of the optic nerve-surface nerve fibre layer, prelaminar 
region, lamina cribrosa region, retrolaminar region 
Arcuate fibres occupy the superior and inferior temporal portions 
of the optic nerve head, with axons from the peripheral retina taking a 
peripheral location. They are more susceptible to glaucomatous damage. 
Papillomacular fibres spread over approximately one third of the 
distal optic nerve, primarily inferior temporally where the axonal 
density is higher. They intermingle with extra macular fibres, which 
explain the retention of central vision during early glaucomatous optic 
atrophy. 
GLAUCOMATOUS DISC CHANGES 
A. EARLY CHANGES 
1. Vertically oval cup 
2. Asymmetry  of the cups> 0.2 between the two eyes 
3. Large cup> 0.5 
4. Splinter haemorrhages on/near the disc margin 
5. Disc pallor 
6. Atrophy of the retinal nerve fibre layer 
B. ADVANCED CHANGES 
1. Marked cupping(cup size 0.7 to 0.9) 
2. Thinning of neuroretinal rim 
3. Nasalisation, bayonetting of vessels. 
4. Laminar dot sign 
5. Retinal arteriole pulsation 
C. GLAUCOMATOUS OPTIC ATROPHY 
White coloured & deeply excavated optic nerve head 
 
PATHOGENESIS OF GLAUCOMATOUS OPTIC ATROPHY 
Several theories were  put forth for the pathogenesis.2 important 
theories are 
1. MECHANICAL THEORY OF MULLER 
Elevated IOP led to direct compression and death of the neurons 
2. VASOGENIC THEORY OF VON –JAEGER 
Structural and functional defects  occurring in glaucoma are due 
to ischemia. Advanced by HAYREY-increase of IOP and fall  of blood 
pressure lead to  fall of  perfusion in  the ocular blood vessels,fall of 
perfusion pressure can  obliterate vessels first in the post laminar and 
retro  laminar region. blood flow in these areas lack the ability of auto 
regulation. optic cupping results from chronic ischemia of the optic 
nerve head. 
CHARACTERISTICS OF GLAUCOMATOUS OPTIC ATROPHY 
1. FOCAL ATROPHY 
2. CONCENTRIC ATROPHY 
3. DEEPENING OF CUP 
4. ADVANCED  GLAUCOMATOUS CUPPING 
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INTRAOCULAR PRESSURE(IOP) 
Normal intraocular pressure is defined as that pressure that does 
not lead  to glaucomatous drainage of the optic nerve head. 
IOP -Factors determining: 
1. Rate of aqueous formation 
2. Resistance to aqueous outflow across trabecular meshwork to 
schlemm’s canal 
3. Level of episcleral venous pressure 
Factors causing long term changes in IOP: 
Heredity, age, sex, race, refractive error 
Factors causing short term changes in IOP: 
Arterial blood pressure, systemic venous pressure, mechanical 
pressure on the globe, plasma osmolarity, blood pH, diurnal variation in 
IOP, seasonal variation in IOP, systemic hyperthermia, general 
anaesthesia, drugs, blockage of aqueous circulation. 
  
GONIOSCOPY 
With goniolens, the beam of light is diverted and this technique of 
biomicroscopic examination of the angle of anterior chamber is called 
gonioscopy. 
TYPES OF GONIOLENS 
1. INDIRECT 
Provides mirror image of the opposite angle e.g., goldman, zeiss, 
posner, sussman, Ritch trabeculoplasty lenses 
2. DIRECT 
 Direct view of the angle  e.g., Barkan, koeppe,Swan Jacob lenses 
PROCEDURE 
Patient is seated upright in the slit lamp. A drop of viscoelastic 
substance is placed in the concavity of the goniolens and with the 
patient looking up, one edge of the lens is positioned in the posterior 
fornix. The upper lid is elevated and the patient is asked to look straight 
ahead. Lens is rotated into position against the eye. When checking 
medial and lateral angles, slit beam should be horizontal, for  superior 
and inferior angles, slit should be vertical. 
ANGLE STRUCTURES SEEN FROM  BEHIND FORWARDS: 
1. Root of the iris 
2. Ciliary band 
3. Scleral spur 
4. Trabecular meshwork and schlemms canal 
5. Schwalbe’s line 
APPLICATIONS 
1. Classification of glaucoma as open angle/closed angle 
2. Localisation of foreign bodies 
3. Abnormal blood vessels in angle 
4. Tumors in angle 
5. Extent of peripheral anterior synechiae 
SHAFFER’S GRADING OF GONIOSCOPY 
IV- 35 -450 - WIDE OPEN 
III-20-350  - OPEN ANGLE 
II-  200       - MODERATELY NARROW 
I  -100       - VERY NARROW 
O  -00       - CLOSED 
VISUAL FIELD DEFECTS 
The field of vision is defined as the area which is perceived 
simultaneously by a fixating eye. The limits of the normal field of vision 
are 60°  superiorly, 75°  inferiorly, 110° temporally, and 60° nasally.  
Traquair,  in his thesis, described an island of vision in the sea of 
darkness . The island represents the perceived field of vision, and sea of 
darkness is the surrounding areas that cannot  be seen. In the light-
adapted state, island of vision has a steep central peak which 
corresponds to the fovea, the  area of greatest retinal sensitivity. 
STATIC PERIMETRY: 
In static perimetry, the size and location of the test target remain 
same. The retinal sensitivity at a specific location is determined by 
varying the brightness of the test target. The shape of the island is 
brought by repeating the threshold measurement at different locations in 
the field of vision. 
KINETIC PERIMETRY: 
  In kinetic perimetry, the stimulus is moved from a nonseeing area 
of the visual field to a seeing area along a fixed meridian. The procedure 
is repeated with the use of the same stimulus along other meridians, 
which is usually spaced every  15 degrees. 
GLAUCOMATOUS  VISUAL FIELD DEFECTS: 
Any clinically or statistically significant deviation from the 
normal shape of the hill of vision is considered as a visual field defect. 
In glaucoma, these defects are either diffuse depressions or localized 
defects that correspond to nerve fiber bundle patterns. 
DIFFUSE DEPRESSION: 
Diffuse depression of the visual field results from an overall or 
widespread or diffuse sinking of the island of vision and this reflect 
diffuse loss of nerve fibers of the retina. Diffuse depression is a 
nonspecific sign that can be caused by many other etiologies other than 
glaucoma. 
NERVE FIBRE LAYER DEFECTS: 
Localized visual field defects in glaucoma usually result from 
damage to the  retinal nerve fiber bundles.   Because of the unique 
anatomy of the retinal nerve fiber layer of retina, axonal damage causes 
characteristic visual field changes. 
The superior and inferior poles of the optic nerve head are more 
prone  to glaucomatous damage. It has been postulated that these areas 
may be watershed areas at the junction of the vascular supply from 
adjacent ciliary vessels. Following are the characteristic patterns of 
visual field damage. 
PARACENTRAL DEFECTS: 
Circumscribed paracentral defects is an  early sign of localized 
glaucomatous damage. The defects may be absolute when first 
identified or they may have deep nuclei which is surrounded by areas of 
less dense involvement. The dense nuclei often are many along the 
course of the nerve fiber bundle. 
ARCUATE FIBRE DEFECTS: 
More advanced loss of arcuate nerve fibers leads to scotoma that 
initiates at or near the  blind spot, arches around the point of fixation, 
and terminates abruptly at the nasal horizontal meridian . An arcuate 
scotoma can be relative or absolute. In the temporal portion of the field, 
it is usually narrow because all the nerve fiber bundles converge onto 
the optic nerve. The scotoma spreads out on the nasal side and will be 
very wide along the horizontal meridian.  
Because of the peculiar anatomy of the horizontal raphe, all 
complete arcuate scotomas end at the nasal horizontal meridian. 
NASAL STEP DEFECT 
A steplike defect in the nasal side  along the horizontal meridian 
results from asymmetric loss of nerve fiber bundles in the superior and 
inferior hemifields. 
TEMPORAL WEDGE DEFECTS 
Damage to nerve fibers in the nasal side of the optic disc may 
result in temporal wedge-shaped defects. These defects are very less 
common than defects in the arcuate distribution. 
Occasionally, they can be seen as the sole visual field defect. 
Temporal wedge defects don’t respect the horizontal meridian. 
BLIND SPOT CHANGES 
Enlargement 
Vertical elongation of the blind spot can occur with the 
development of a Siedel scotoma, an early arcuate defect that get 
connected with the blind spot.  
Peripapillary atrophy, which frequently follows  glaucomatous 
damage, particularly in elderly patients, also can cause enlargement of 
the blind spot 
Baring 
Baring of the blind spot can be physiologic or pathologic. 
Physiologic baring of the blind spot is usually an artifact of kinetic 
perimetry. The inferior retina is minimally sensitive than the superior 
retina, so an isopter plotted at threshold in the inferior central retina can 
result in superior baring of the blind spot.  
Physiologic baring of the blind spot usually is restricted to a 
single central isopter in the superior visual field . 
  
VISUAL ACUITY 
Visual acuity is  considered as a measure of form sense, so it 
refers to the spatial  limit of visual discrimination. Visual angle is the 
angle subtended at the nodal point of the eye by the physical dimensions 
of an object in the visual field. 
In  terms of visual angle,visual acuity is defined as the reciprocal 
of the minimum resolvable visual angle measured in terms of minutes of 
arc for a standard test pattern. 
COMPONENTS OF VISUAL ACUITY: 
1. MINIMUM VISIBLE - ability to determine whether or not an 
object is present in an otherwise empty visual field   
2. RESOLUTION-discrimination of two spatially separated targets 
3. RECOGNITION-it is the facility by which an individual not 
only discriminates the spatial characteristics of the test pattern but 
also identifies the patterns with which the person has had some 
experience  
4. MINIMUM DISCRIMINABLE / HYPERACUITY – spatial 
distinction by an observer where the threshold is much lower than 
the ordinary acuity 
FACTORS AFFECTING VISUAL ACUITY: 
Stimulus related factors: 
1. Luminance 
2. Stimulus geometry 
3. Contrast  
4. Influence of wavelength 
5. Stimulus exposure 
6. Interactive effects of two targets 
Observer related objects: 
1. Retinal locus of stimulation 
2. Pupil size 
3. Accommodation 
4. Effect of eye movements  
5. Meridional variation in acuity 
6. Optical elements of the eye 
7. Developmental aspects of eye 
MEASUREMENT OF VISUAL ACUITY FOR DISTANT VISION 
IN SCHOOL CHILDREN & ADULTS 
SNELLEN’S CHART 
Principle 
The two distant points are visible as separate only when they 
subtend at an angle of 1 min at the nodal point of the eye. Snellen’s 
Chart-consists of series of black capital letters on a white background, 
arranged in lines, each progressively diminishing in size, lines 
comprising the letter have such a breadth that they will subtend an angle 
of 1 min at the nodal point. Each letter is so designed that it fits in a 
square, the sides of which are five times the breadth of the constituent 
lines .thus at the given distance, each letter subtends at an angle of 5 
mins at the nodal point of the eye. The end point is the letter 
recognition.  
LANDOLT’S TEST TYPES: 
It is similar to that  of snellen’s, except that in it, instead of the 
letter, the broken circles are used the end point is the detection of 
orientation of the break in the circle. 
PROCEDURE OF TESTING: 
For testing distant visual acuity patient is seated at a distance of 
6m from the snellen’s chart, so that the rays of light are exactly parallel 
& the patient exerts minimal accommodation. Chart should be properly 
illuminated(not < 20 ft candles). 
When the patient is able to read upto 6m line, visual acuity is 
recorded as 6/6,which is normal. Depending upon the smallest line the 
person can read from the distance of 6 m, his vision is recorded as 
6/9,6/12,6/18,6/24,6/36 &6/60 respectively. Depending upon the 
distance from which the person can read the top line, vision is recorded 
as 5/60,4/60,3/60,2/60 & 1/60 respectively. 
If the patient is not able to read the top line still, he is asked to 
count fingers, graded as CF-3’,CF-2’,CF-1’ & CFCF. If the patient fails 
to count fingers, hand movements(HM)  are recorded. If still not seeing, 
perception of light (PL) tested and recorded.  
VISUAL ACUITY IN PRESCHOOL CHILDREN: 
3 to 5 yrs: 
Illiterate E-cutout test, tumbling E test, isolated hand figure test, 
Sheridan-Gardiner HOTV test, pictorial vision charts, broken wheel test, 
Boek candy bead test, Light home picture cards. 
2 to 3 yrs: 
Dot visual acuity, coin test, miniature toy test 
1 to 2 yrs: 
Marble game test, Sheridan’s ball test, Boek’s candy test, Worth’s 
ivory ball test 
INFANTS: 
Optokinetic nystagmus test, preferential looking test, visually 
evoked response, catford drum test, Cardiff acuity cards test, indirect 
assessment with the milestones 
MEASUREMENT OF VISUAL ACUITY FOR NEAR VISION: 
1. Jaeger’s chart 
2. Roman test types 
3. Snellen’s near vision test types 
PROCEDURE OF TESTING: 
Patient is asked to read the near vision chart kept at a distance of 
25 to 35 cm, with a good illumination. The smallest type which the 
person can read comfortably is recorded. A note of the approximate 
distance at which the near vision chart is held should also be made.  
COLOUR VISION 
Glaucoma may cause an acquired colour vision defect in either 
red green or blue yellow axis, blue yellow more frequently affected. 
The degree of colour vision loss in chronic open angle glaucoma 
patients correlates with the extent of visual field loss. Several theories 
have been described  in order  to explain the predominance of tritan-like 
defects in POAG, including: a) short wavelength cones or their neuronal 
connections are less resistant to the effects of raised IOP, and b) there is 
selective damage to blue–yellow sensitive ganglion cells or their axons. 
Blue–yellow ganglion cells usually  have larger receptive fields, are 
bigger than red–green cells and have a unique morphology and has a 
connectivity to second order neurons, which make blue–yellow ganglion 
cells more susceptible to IOP-related damage. 
PSEUDO-ISOCHROMATIC PLATES 
These are the most largely used clinical tests to assess colour 
vision because they are portable and easy to use. In general, these tests 
are most useful for the detection of congenital anomalies. Ishihara plates 
are the most efficient and useful pseudo-isochromatic test. The major 
limitations of the Ishihara plates are that they do not contain designs for 
the detection of tritan defects, and that patients require atleast 6/18 
visual acuity to resolve the test. Consequently, the Ishihara test is not 
appropriate for the assessment of the majority of the acquired anomalies, 
which are frequently associated with tritan-type defects.  
The H-R-R(Hardy-Rand-Rittler) test was designed for the 
detection of congenital, including tritan, deficiencies and has a series of 
plates having different colour difference steps allowing grading of 
protan, deutan, and tritan defects. The minimum visual acuity required 
for interpretation of the test is 6/60 only. Moderate and severe acquired 
type III deficiencies are detected by the H-R-R plates . 
Farnsworth Munsell 100 hue test 
The subject should arrange the hues in the order of the color 
spectrum.  
  
CONTRAST SENSITIVITY 
It is the ability of the eye to perceive changes in the luminance 
between regions which are separated by definite borders. 
Contrast sensitivity is affected by factors like age, refractive 
errors, glaucoma, ambylopia, diabetes, optic nerve diseases, lenticular  
changes. 
TYPES OF CONTRAST SENSITIVITY 
SPATIAL SENSITIVITY:  
Refers to stripped pattern at various levels of contrast and spatial 
frequencies. High spatial contrast is perceived by the parvocellular 
retinal  ganglion cells. 
The test can distinguish glaucomatous eyes from normal eyes or 
eyes with ocular hypertension. 
TEMPORAL CONTRAST SENSITIVITY 
Contrast sensitivity is generated for time related(temporal)  
processing  in the visual system by presenting a uniform target field 
modulated sinusoidal in time rather as a function  of spatial position. 
Critical flicker frequency is mediated by the magnocellular retinal 
ganglion cells. 
Losses have been reported in patients with glaucoma and 
glaucoma suspects. 
MEASUREMENT OF CONTRAST SENSITIVITY: 
Threshold level: 
Grating frequencies & contrast  below which resolution is 
impossible. Reciprocal of this threshold  gives the contrast sensitivity 
Measured as (Lmax-Lmin)/(Lmax+Lmin),where L is the luminance 
recorded by  photocells scanning  across the gratings 
Deficits are of 3 types: 
1. High frequency type-increasing loss at high frequency 
2. A level loss type-similar loss for all spatial  frequencies 
3. Selective loss type-deficits in a narrow band of spatial frequencies 
METHODS OF MEASURING CONTRAST SENSITIVITY 
1. Arden gratings 
2. Cambridge low contrast gratings 
3. Pelli-Robson chart-MOST COMMONLY EMPLOYED 
The chart is viewed at one metre and the letters of each row are of 
equal size with decreasing contrast of 0.15 log units for every group of 3 
letters. 
4. Vistech chart 
Use of contrast sensitivity in glaucoma: 
Significant reduction in contrast sensitivity at medium to  high 
spatial frequencies  found, this change in modulation function is related 
to the loss of neuronal cells, either in the retina or along the visual 
pathway to the visual cortex 
  
PELLI-ROBSON CHART 
 
 
 
Fig 1.Pelli Robson Chart-chart for Contrast Sensitivity. 
 
 
 
 VISUAL EVOKED POTENTIAL IN GLAUCOMA 
When light falls on the retina, a series of nerve impulses are 
generated and passed on to the visual cortex via the visual pathway, 
which are recorded by EEG technique is known as visual evoked 
potential. It is the only objective technique available to test  the 
functional state of the  visual pathway beyond the ganglion cells. It is of 
2 types-FLASH & PATTERN  VEP. 
FLASH VEP: 
• Recorded by an intense flash illumination. 
• Indicates light has been perceived  by the visual cortex 
• Not affected by opacities in the visual cortex 
Uses 
1. Assess the integrity of macula and visual pathway in infants, 
mentally retarded  and aphasics 
2. Differentiate organic & psychological blindness 
3. Useful in eyes with opaque media 
PATTERN VEP: 
• Recorded using patterned stimulus as in  the checker board 
• Depends on form sense and gives a rough estimate of visual 
acuity 
PROCEDURE: 
The room should be dark enough. Test mono-ocularly with the 
other eye covered. Stimulus used is a checkerboard pattern -two 
reversal/sec. Stimulus rates of 1-2 Hz are used.The recommended 
recording time window (ie, sweep length) is usually250 ms. Seating 
distance is about 70-100 cm from the monitor screen.Fix the gaze at a 
colored dot, usually red color, in the center of the screen.  
VEP RECORDING: 
Ag/AgCl cup electrodes are fixed with the collodion in the 
following positions: active electrode in Oz (2cms above the inion), 
reference electrode in  Fz (on the frontal bone), Cz at the frontal bone 
and ground electrode on left arm.  
After the stimulus was over ,NPN complex will be obtained. The 
waves are identified. The values will appear in the table. Repeat the 
procedure & get an another record. Display both the recordings and 
superimpose them for showing  the reproducibility of the test results. 
Repeat the procedure for the other eye. 
USE 
Increased sensitivity in detecting axonal conduction defects 
NORMAL VERSUS ABNORMAL RECORD OF VEP 
Pattern VEP : 3 wave pattern 
• Initial negative wave(70-100ms)followed by 
• Positive wave(100-130ms) followed by 
• Negative wave(150-200ms) 
Response Amplitude 
• Normal-10 To 25 Micro Volts 
• Abnormal-  <10 Micro Volts 
Flash VEP 
Primary response-M-shaped multiphasic curve with 2 positve and 
2 negative waves, followed by a series of highly secondary variables  
amplitude and latency measurements  are same as that for flash  VEP 
ROLE OF VEP IN GLAUCOMA: 
1. Lesions Affecting The Optic Nerve Conduction - amplitude 
reduced, latency prolonged 
2. In Detecting Central Field Defect. 
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ELECTRORETINOGRAM (ERG) 
ERG is the record of changes in the resting potential of the eye 
induced by a flash of light. 
Measured in dark adapted eye with the active electrode (fitted on 
a contact lens) placed on the cornea and the reference electrode  placed 
on the forehead. 
ERG is useful in detecting functional abnormalities of outer retina 
(upto bipolar cells) 
ERG is normal in diseases involving ganglion cells and higher 
visual pathway  
Normal Record Of ERG 
a-wave :  Negative wave, arising from rods & cones 
b-wave : Large positive wave, generated by the muller cells, 
but represents the  activity of the bipolar cells 
c-wave : Positive wave ,representing metabolic activity of 
pigment epithelium scotopic and photopic responses 
can be elicited in ERG. Foveal ERG provides 
information  about macula  
Clinical Applications Of ERG 
1. Diagnosis and prognosis of retinal disorders-retinitis pigmentosa, 
leber’s congenital amaurosis, retinal ischemia, chorioretinal 
degenerations  
2. Assess retinal function in the presence of dense cataract and 
corneal opacity 
3. Retinal function of the babies 
Abnormal ERG Response 
1. Supernormal Response 
Amplitude greater than  2 standard deviation above the mean for 
both ‘a’ and ‘b’  waves or only the ‘a’ wave seen in subtotal retinal 
circulatory disturbances of retina, albinism, early siderosis bulbi 
2. Subnormal Response 
A potential <  2 standard deviation below the mean normal 
          Indicates that large area of retina is not functioning 
Seen in early cases of retinitis pigmentosa, chloroquine & quinine 
toxicity ,retinal detachment, systemic cause-vit A deficiency, 
hypothyroidism, mucopolyssacharidosis, anemia 
3. Extinguished Response 
Complete absence of response 
          Indicates total failure of rod and cone function 
Seen in advanced cases of retinitis pigmentosa, complete retinal 
detachment, advanced siderosis bulbi, choroideremia, Leber’s 
congenital amaurosis, luetic chorioretinitis 
4. Negative Response 
Large a-wave 
          Indicates gross disturbances of retinal circulation 
Seen in Arteriosclerosis, Giant cell arteritis,  
Central retinal artery and vein occlusions  
Role of ERG in open angle glaucoma: 
Amplitude of the pattern  ERG  reduced and the latency will be 
prolonged  significantly. 
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           GLAUCOMA- CLASSIFICATION 
Clinico -etiologically glaucoma may be classified as  
A) Congenital And Developmental Glaucomas 
1. Primary congenital glaucoma (without associated 
anomalies) 
2. Developmental glaucoma (with associated anomalies) 
B) Primary Adult Glaucomas 
1. Primary open angle glaucoma(POAG) 
2. Primary angle closure glaucoma(PACG) 
3. Primary mixed mechanism glaucoma 
C) SECONDARY GLAUCOMAS  
  
PRIMARY OPEN ANGLE GLAUCOMA 
Primary open-angle glaucoma is described as optic nerve damage 
from multiple possible causes that is chronic and progresses over time, 
with a loss of optic nerve fibers that is characteristic of the disease. 
       In addition to the loss of optic nerve fibers, primary open-angle 
glaucoma  is   characterized by open anterior chamber angles, visual 
field abnormalities, and intraocular pressure that is too high . 
Incidence of glaucomatous damage in people who previously had 
no signs of glaucoma to be about 2.6-3% for intraocular pressures of 21-
25 mm Hg, 12-26% for intraocular pressures of 26-30 mm Hg, and 
approximately 42% for those intraocular pressures higher than 30 mm 
Hg. Worldwide,  More than 3 million people are blind in both eyes from 
primary open-angle glaucoma.   More than 2 million people will develop 
primary open-angle glaucoma  each yr. 
  Blacks are considered to have a 3-4 times greater risk of 
developing primary open-angle glaucoma than whites. Blacks are also 6 
times more likely to have optic nerve damage than whites.  
Being older than 40 years is considered to be a risk factor for the 
development of primary open-angle glaucoma, with up to 15% of people 
affected by the seventh decade of life. However, the disease itself is not 
limited to only middle-aged and elderly individuals. 
ETIOPATHOGENESIS 
Decreased Aqueous Outflow 
Due to  increased resistance to  outflow  caused by age related 
thickening  and sclerosis of the trabeculae and an absence of giant 
vacuoles in the cells lining the canal of schlemm.  
Predisposing Factors 
Heredity - Polygenic inheritance,risk in siblings-10%,risk in 
offspring-4% 
Age - Common between 5th & 7th decades 
Race - More severe in black 
Myopes, Diabetics, Cigarette Smoking 
High Blood Pressure, Thyrotoxicosis 
  
Steroid responders: 
a. Normal persons receiving top. dexamethasone eye drops  3-4t/d 
for 4-6 weeks, 60%-low(IOP elevation less than 6mm of Hg), 
30%-intermediate(between 6& 15 mm of Hg),  5%-high(IOP>31 
mm of Hg & pressure rise > 15 mm of Hg) 
b. In POAG patients, 5%-low,10-50%-intermediate,45-90%-high                               
CLINICAL FEATURES 
• Disease is usually asymptomatic 
• Mild head ache, eye ache 
• Occasionally, patient may notice a visual field defect 
• Frequent changes in presbyopic glasses 
• Delayed dark adaptation 
EVALUATION OF POAG 
The patient suspected to have POAG should be done all routine 
investigations like  visual acuity, slit lamp biomicroscopy, tonometry, 
gonioscopy, fundus examination, perimetry, specific investigations  like 
color vision, visual  evoked potential (VEP), electroretinogram, contrast 
sensitivity, also done whenever necessary to know the visual potential in 
POAG.  
OCULAR ASSOCIATIONS 
• High myopia 
• Fuch’s endothelial dystrophy 
• Retinitis pigmentosa 
• Central retinal vein occlusion 
• Primary retinal detachment 
MANAGEMENT 
Aims Of Treatment 
To lower IOP to a level,where further visual loss will not occur 
MEDICAL THERAPY 
Basic principles: 
1. Identification of target pressure(below which glaucomatous  
damage will not progress) 
2. Single drug therapy ,usually a beta blocker/prostaglandin  
analogue 
3. Follow up after 4 weeks-fall in IOP of  >4 mm of Hg is 
significant 
• If response is satisfactory, follow up after 2 months  &  3-4 
months thereafter 
• If response is unsatisfactory, another drug substituted for the 
initial drug 
• If response  is still unsatisfactory, another drug 
added/combined preparation  substituted 
4. Monitoring of therapy by disc changes, field changes, gonioscopy 
essential 
SINGLE DRUG THERAPY 
1. Topical Beta Blockers 
First choice drug ,lowers IOP by  reducing the aqueous secretion 
due to their effect on  beta receptors in the ciliary processes. 
Timolol-0.25,0.5%:1-2 times daily,most commonly used,not  
used in  asthmatics, heart block.  
Betaxolol-0.25%,2 times/day, selective beta 1 blocker, useful in 
cardiopulmonary diseased. 
Levobunolol-0.25,0.5%:1-2 times/day, long duration of action. 
Carteolol-1%:1-2 times daily, good in patients  with  
hyperlipidemias. 
2. Pilocarpine 
1,2,4% :3-4 times/day. Contracts longitudinal muscle of ciliary 
body & opens spaces in trabecular  meshwork, increasing outflow . Not 
preferred nowadays-due to spasms of accommodation, miosis, axial 
lenticular opacities . 
3. Prostaglandin Analogues 
Latanoprost (0.005%), travoprost (0.004%), bimatoprost (0.03%) 
They decrease  the IOP  by increasing the uveoscleral outflow of 
aqueous. 
4. Carbonic Anhydrase Inhibitors 
Dorzolamide (2%: 2-3 times/day)-lowers  IOP by decreasing 
aqueous secretion . 
5. Adrenergic Drugs 
Epinephrine hydrochloride (0.5,1,2%:1-2 times/day) and 
Dipivefrine hydrochloride (0.1%:1-2 times/day) - lowers IOP by 
increasing the aqueous  outflow by stimulatin the beta receptors in the 
outflow system, causes allergic  reaction  & long term use  produces 
failure of filtration surgery. 
Brimonidine (0.2%:2 times/day) - selective alpha 2 adrenergic 
agonist, lowers IOP by decreasing aqueous  production,causes increased 
allergic reactions. 
Combination Drug Regimen 
If the single drug is not effective,One drug that increases aqueous 
outflow (latanoprost/ brimonidine/ pilocarpine) and  one drug that 
decreases aqueous production (timolol/ brimonidine/ dorzolamide) may 
be used. 
Other Supplemental neuroprotective agents 
Calcium Channel Blockers- Flunarizine, lomerizine, nifedipine,  
verapamil  diltiazem , Nilvadipine  
Antioxidants - Co Q10,vitamin E, Gingko Biloba, Melatonin 
Nitric Acid Synthase Inhibitor - Aminoguanithidine. 
Nmda Receptor Antagonists - Memantine, Flupritine, Riluzole. 
Immune Mediators - Glatiramer acetate, Geranyl geraylacetone, 
Amyloid beta antibodies 
Apoptosis Inhibitors - Caspase-3 inhibitors, TNF-alpha 
inhibitors,Calpain inhibitors 
Newer Drug - Citicholine 
Citicoline 
• Citicoline is Cytidine -5’-Diphosphocholine 
• improves retinal & cortical responses in glaucoma  
• activates the biosynthesis of phospholipids in neuronal 
membranes increases the metabolism of cerebral structures, 
inhibits phospholipid degradation 
• has effects on the visual system that has been recently suggested  
by  the improvement of visual acuity,VEP responses and contrast 
sensitivity. 
  
ARGON/DIODE  LASER 
TRABECULOPLASTY(ALT/DLT) 
Indications 
1. Uncontrolled IOP despite maximal medical therapy 
2. Non-compliance to medical therapy 
Treatment regime: 
50 spots on the anterior half of the trabecular  meshwork over 
1800 
Hypotensive Effect 
• -increasing outflow facility possibly by producing  collagen 
shrinkage on the inner aspect of the trabecular meshwork  and 
opening the intra trabecular spaces. 
• -lowers IOP by12-16 mm of Hg  
Complications 
Transient acute rise in Inflammation, hemorrhage, uveitis, 
peripheral anterior synechiae & reduced accommodation 
  
                        SURGICAL THERAPY 
INDICATIONS 
1. Uncontrolled glaucoma despite maximal medical  therapy and 
laser trabeculoplasty 
2. Non-compliance of medical therapy,non-availability of ALT 
3. Failure of medical therapy 
4. Eyes with advanced  disease i.e.,having high IOP ,advanced 
cupping, advanced  field loss 
FILTRATION SURGERY 
Mechanism of Filtration 
1. Fistula is created around the margin of scleral flap, through which 
aqueous flows from the anterior chamber into the subconjunctival 
space 
2. If the tissue is dissected posterior to the scleral spur, cyclodialysis  
may be produced  leading to increased uveoscleral outflow 
Complications 
Postoperative shallow anterior chamber, hyphaema, iritis,cataract,  
 
endophthalmitis. 
 
 
 
 
 
PART TWO 
  
AIMS AND OBJECTIVES OF THE STUDY 
To analyse the visual functions in primary open angle glaucoma 
patients and to assess the progression/regression of visual damage in 
primary open angle glaucoma patients. 
To study about the neuroprotective role of citicholine with VEP 
assistance. 
MATERIALS AND METHODS 
STUDY DESIGN : Prospective study 
DURATION OF THE STUDY : 2 Yrs (JUNE 2010-JUNE 2012). 
INCLUSION CRITERIA : All POAG patients on medical therapy 
only 
EXCLUSION CRITERIA : 1. Patients who underwent previous 
ocular surgery. 
  2. All angle closure patients. 
  3. All secondary open angle 
glaucomas. 
 
METHODOLOGY: 
100 primary open angle glaucoma patients, who came to 
glaucoma clinic at Regional Institute of Ophthalmology, Chennai, 
during the period june 2010 to june 2012 were evaluated completely for 
the visual functions. 
Visual acuity (snellens chart), colour vision (ishihara’s chart), 
contrast sensitivity (Pelli Robson chart) was done for all patients. Visual 
evoked potential(VEP) was done for 30 patients, ERG 
(electroretinogram) was done for 5 patients. Progression  or regression 
of the damage in POAG was assessed using these visual function tests 
after the initiation of medical therapy every 6 months for 2 yrs. 
30 patients were started on tablet citicholine and the 
neuroprotective role of the drug assessed with VEP. A baseline VEP 
was done in all 30 patients. For all the 30 patients, tab. citicholine 
500mg bd given for 60 days .After 2 months of citicholine,2nd VEP was 
done for all the 30 patients .After a wash out of 90 days,3rd VEP was 
done for all 30 patients. 12 patients lost their follow up,3 patients 
developed gastrointestinal symptoms like  vomiting and diarrhoea,so the 
drug was stopped in these 3 patients. 
Then these 15 patients are grouped into groups  A & B,each 
consisting of 7 patients.Group B was given citicholine  for 2 months and 
group A was not given citicholine and the wash out was extended for a 
period of 3 more months. In group B patients,4th VEP was taken after 
finishing the second course of citicholine,at the end of seventh month.In 
group A patients,4th  VEP was taken at the end of eighth month. In 
group B patients,a wash out of  90 days was given,and then at the end of 
the tenth month,5th VEP was taken.During the entire period of treatment 
with citicholine, and the whole wash out period for all glaucoma 
patients, no other general pharmacological treatments were given, but 
the topical antiglaucoma drugs was continued. 
All the subjects were examined in detail and glaucoma workup 
was done. Demographic data like age, sex and locality were included. 
Detailed history of presenting complaints like defective vision, 
headache, coloured halos, redness, pain, watering and history of any 
associated systemic conditions  (diabetes mellitus and hypertension) was 
taken. Family history of glaucoma and history of any topical or systemic 
medications and past history of ocular surgery, laser procedures and 
ocular trauma were obtained. 
Best corrected visual acuity with refraction was done for all 
subjects. Intraocular pressure was recorded with Goldmann applanation 
tonometry and corrected for variations in central corneal thickness 
measured by ultrasonic pachymetry.Stereobiomicroscopic examination 
of optic disc was done using + 90D lens.Gonioscopy was carried out 
using a Goldmann single mirror gonioprism with low ambient 
illumination. 
ASSESSMENT OF PARAMETERS: 
Visual acuity, Intraocular pressure measurement, colour vision, 
contrast sensitivity was done for all patients initially and also during the 
follow up period. VEP (visual evoked potential) was done for 30 
patients and the neuroprotective role of citicholine was assessed by 
recording the cortical responses using VEP. ERG (Electroretinogram) 
was done for 5 patients. Once in 6 months, progression  or  regression of 
the damage in POAG was assessed after the medical therapy every 6 
months by doing visual function tests. Depending upon the response to 
medical management, we modify the medical therapy or go for alternate 
therapy. 
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FAMILY HISTORY: 
       About 6 people among the 100 patients had a significant family 
history of glaucoma. In the Rotterdam Eye Study, the risk of having 
glaucoma was 9.2 fold for individuals who had a relative with 
glaucoma. 
 
INTRAOCULAR PRESSURE 
For all the 100 patients,intraocular pressure was measured using 
Goldmann applanation tonometer.10 eyes had normal intraocular 
pressure and the remaining people had intraocular pressure more than 
21mm of Hg. 
6, 6%
94, 94%
PERCENTAGE OF FAMILY HISTORY 
IN THE STUDY PATIENTS.
family history
no fh
 Intraocular pressure  
(mm of  hg) No. Of eyes Percentage P value 
<21 10 10% 
 
0.050* 
>21 190 90% 
TOTAL 200 100% 
 
CENTRAL CORNEAL THICKNESS (CCT) AND 
INTRAOCULAR PRESSURE (IOP): 
Central corneal thickness <550 microns is more significantly 
associated with increased intraocular pressure and hence associated with 
primary open angle glaucoma and glaucoma suspect. Among  200 
eyes,52  people had CCT  less than 520µ,97 had CCT between 520-
550µ and 51 have CCT more than 550µ. 
IOP  
(mm of Hg) 
CCT 
TOTAL
<520µ 520-550µ >550µ 
<21 
3 5 2 10 
30% 50% 20% 100.0% 
>21 
49 92 49 190 
25.8% 48.4% 25.8% 100.0% 
TOTAL 52 97 51 200 
 26.0% 48.5% 25.5% 100.0%
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 COLOR VISION AND CONTRAST SENSITIVITY: 
12 eyes which presented with relative afferent pupillary defect 
had a color vision defect and a defect in the contrast sensitivity. In 20 
eyes, color vision could not be tested due to multiple reasons like media 
opacities, glaucomatous optic atrophy. The remaining 168 eyes were 
found to be normal. This is similar to the previous studies done. 
 
Color vision No. Of eyes 
Contrast 
sensitivity 
No. Of 
eyes 
Percentage 
Normal 168 Normal 168 84% 
Defective 12 Cs loss 12 6.0% 
Not done 20 Not done 20 10.0% 
Total 200 Total 200 100.0% 
 
  
VISUAL EVOKED POTENTIAL: 
30 patients were selected and the neuroprotective role of 
citicholine was assessed using visually evoked potential(VEP)  in them.  
First Period Of Evaluation: 
Among 30 patients who received citicholine, after the first dose of 
citicholine (60 days),4 patients had the same latency and amplitude as 
baseline VEP, while the remaining 16 patients had reduced latency and 
increase in amplitude. After the wash out period(150 days),mild increase 
in latency and decrease in amplitude was found. 
Second Period Of Evaluation: 
After the second dose of citicholine (210 days),in group B 
patients, except for 2 patients, all other  patients showed a decrease in 
latency and increase in amplitude. In group A(240 days),those who are 
in the wash out period for three months, prolonged latency in 2 patients 
and same amplitude with same latency as before(baseline) in all other 
patients were seen. In group B, after a wash out of 90 days(300 
days),there was a decrease in latency and increase in amplitude. No 
significant changes in IOP were found in any of the subjects tested. 
 VEP 
P100 
LATENCY 
(Mean +  SD)  
in ms 
Amplitude 
(Mean + SD )  
in  microVolt 
p value 
Baseline 118.7+8.15 5.6+2.50 
 
 
 
p < 0.001** 
 
 
After citicholine  
(60 days) 
107.2+6.89 8.6+2.13 
After wash out 
(120 days) 
112.3+8.02 7.0+2.40 
Group B 
210 days 104.7+5.95 8.8+1.23 
300 days 110.2+6.64 7.1+1.01 
Group A -240 days 116.7+5.50 5.8+1.50 
 
These electrophysiological data showing that citicholine improves 
the cortical responses confirms all that was previously suggested by 
psychophysical analysis. In VEP analysis, dopaminergic-like activity of 
citicholine mainly induces the shortening of VEP latency. After 
treatment with citicholine, reduced retinocortical time was observed as 
evidenced by the decreased P100 latency and the increased N75-P100 
amplitude of VEP. 
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In our study, we have assessed the long term effect of citicholine. 
In glaucoma patients in which only one period of treatment was 
performed (gp A), after  3 months of wash out, we observed that the 
therapeutic effects were still present, whereas after 6 months of 
washout, all electrophysiological  parameters were similar to those 
observed before the start of the treatment. This suggests that retinal and 
cortical responses are still improved at 3 months of wash out while it is 
not possible to observe any therapeutic effect after 6 months of wash 
out. 
ELECTRORETINOGRAM(ERG): 
For five patients, ERG was done before and after citicholine and 
there was a significant decrease in the latency and increase in the 
amplitude 
PERG LATENCY MEAN+ SD P VALUE 
BASELINE 69.3+ 2.85 P-0.308 
AFTER CITICHOLINE 62.3+ 3.10 P-0.000** 
 
PERG AMPLITUDE MEAN + SD P VALUE 
BASELINE 0.69+0.35 P-0.856 
AFTER CITICHOLINE 1.02+0.40 P-0.003** 
 
FOLLOW UP: 
All the 100 patients were followed up every 6 monthly for 2 
years.15 patients didn’t come for regular follow up. The following data 
were analysed. 
INTRAOCULAR  PRESSURE: 
After starting treatment, the intraocular pressure reduced from an 
initial mean value of  25.60 to18.70 after 2 yrs follow up. This was 
similar to the studies done earlier. 
IOP 
No. of  
eyes 
Mean 
Std. 
deviation 
Minimum 
IOP 
Maximum 
IOP 
P 
value 
First visit 200 25.60 6.713 16 58  
 
 
<0.001
6th month 200 19.93 2.988 14 34 
1 yr 194 19.10 2.627 14 30 
1.5 yr 170 18.91 3.808 14 46 
2 yr 170 18.70 3.192 16 30 
 
These data were analysed using Friedman test which is used for 
comparing the k related samples from the analysis, a p value of < 0.001 
is obtained, wich proves the reduction in IOP is significant. 
OPTIC NERVE HEAD EXAMINATION: 
During the first visit, 70.5% of the eyes were having CD ratio of 
0.4- 0.7%,1.1% were <0.4 and 28.4% were  having CD ratio> 0.7.After 
2 years of follow up,75.9% of the eyes were having a CD ratio of 0.4-
0.7,1.3% were  < 0.4,22.8% were having CD ratio  of  >0.7. 
PT.VISITS No. of eyes 
Percentage of eyes with CDR(%) 
< 0.4 0.4-0.7 > 0.7 
First visit 200 1.1 70.5 28.4 
6th month 200 1.1 71.0 28.0 
1 yr 194 1.2 73.2 25.6 
2 yr 170 1.3 75.9 22.8 
P value  0.062 0.011* 0.006** 
 
Thus by analyzing these data using Pearson Chi square test and 
Friedmann test, it was proved that there is a progression in the CD ratio 
of 0.4 to 0.7 group over the 2 yrs avnd the other 2 groups remain more 
or less stationary. 
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VISUAL ACUITY: 
After 2yrs of follow up,94 eyes(50%)  were with good visual 
acuity,66 eyes (35%) were 6/12 to 5/60,25 eyes(13.4%)  were 5/60  to 
PL+, 3 eyes(1.6%) were no PL. Thus there was no significant decline in 
the visual acuity. 
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RELATION OF ONH AND CCT: 
In patients with central corneal thickness less than 550µ,there was 
significant changes  in the  optic nerve head, showing a corresponding 
increase in the cup disc ratio. In patients with ONH- CDR> 0.7,during 
the first visit, CCT less than 550µ was 26%.After 2 yrs of follow up, 
with people who had CCT less than 550µ,ONH > 0.7 was 28.7%. 
VISITS 
NO.  
OF EYES ONH 
CCT(%) TOTAL 
(%) P value 520µ 520-550µ >550µ
FIRST VISIT 200 
< 0.4 2.0 3.3 10.0 4.7 
P<0.402 0.4-0.7 72.0 72.8 60.0 69.3 
>0.7 26.0 23.9 30.0 26.0 
6TH MONTH 200 
<0.4 2.1 3.3 8.3 4.3 
P<0.372 0.4-0.7 70.8 72.8 62.5 69.7 
>0.7 27.1 23.9 29.2 26.1 
1 YR 194 
<0.4 2.2 3.6 7.7 4.2 
P<0.363 0.4-0.7 68.9 72.3 64.1 69.5 
>0.7 28.9 24.1 28.2 26.3 
2 YR 179 
<0.4 2.2 3.8 8.1 4.3 
P<0.042* 0.4-0.7 66.7 72.2 68.9 69.9 
>0.7 31.1 26.1 27.0 28.7 
 
Using Chi square tests, p value was calculated and it was found to 
be significant. 
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SUMMARY 
 The average age of presentation of  POAG in the study was 
between 50-70 yrs. - there was a male preponderance, males 
amounting to 64%,females amounting to 34%. 
 Most of the people (67%)  in the study were from urban 
population.   
 About 10 people were associated with diabetes mellitus,11 were 
hypertensives,4 were asthmatics,9 had both diabetes mellitus and 
hypertension,1 had ischemic heart disease. 
 About 6(6%)  people among the 100 patients had a significant 
family history of glaucoma. 
 During  initial presentation,10(10%) eyes had normal intraocular 
pressure and the remaining people(90%)  had intraocular pressure 
more than 21mm of Hg. 
 Among  200 eyes,52  people had CCT  less than 520µ,97 had 
CCT between 520-550µ and 51 have CCT more than 550µ. 
 About 1.1% of the patients had CDR of  less than 0.4,70.5% had  
CDR of 0.4- 0.7 and 28.4% had a CDR of more than 0.7. 
 In automated perimetry,63(32.1%) eyes were found to have mild 
defects, 53(27%) have  moderate field defects like superior 
arcuate, inferior arcuate, paracentral, fixation, nasal step defects, 
48(24.5%) were found to have biarcuate and tubular defects. 
32(16.3%) were not done automated perimetry due to poor vision. 
 About 96 eyes (50.5%) had a mild damage, 55 eyes (28.9%) had 
moderate damage and 39 eyes (20.6%) had severe damage. 
 Visual acuity was normal in 102 eyes (51%), 6/12 to 5/60 in 
69eyes (35%),5/60 to PL+ in 25 eyes(13%), no PL in 4 eyes(1%). 
 About 54 patients are myopes,15 are hypermetropes and 2 had 
myopic Astigmatism. 
 12 eyes which presented with relative afferent pupillary defect 
had a color vision defect and a defect in the contrast sensitivity. 
 About 136 eyes(68%) were started initially on a single drug 
regime,50eyes (25%) were on a double drug regime and 4 
eyes(2%) were on a triple drug regime. 
 After 2yrs of follow up, 94 eyes(50%)  were with good visual 
acuity,66 eyes (35%) were 6/12 to 5/60,25 eyes(13.4%)  were 
5/60  to PL+,3 eyes(1.6%) were no PL. Thus there was no 
significant decline in the visual acuity. 
 After starting treatment, the intraocular pressure reduced from an 
intial  mean value of  25.60 to18.70 after 2 yrs follow up. p value 
was 0.001 showing the significant reduction in the intraocular 
pressure. 
 After 2 years of follow up,75.9% of the eyes were having a CD 
ratio of 0.4-  0.7,1.3% were  < 0.4,22.8% were having CD ratio  
of  >0.7. It was proved that there is a progression in the CD ratio 
of 0.4 to 0.7 group over the 2 yrs and the other 2 groups remain 
more or less stationary. 
 There was a significant increase in the progression of fields to 
tubular field defects and biarcuate field defects (28.9%) during 
the 2yr visit .p value also proved to be significant. 
 In patients progressing to severe damage(ONH >0.7),color vision 
and contrast sensitivity was defective. 
 In patients with ONH- CDR> 0.7,during the first visit, CCT less 
than 550µ was 26%.After 2 yrs of follow up, with people who had 
CCT less than 550µ,ONH > 0.7 was 28.7%.P value OF 0.042 
showed its significance. 
 For five patients, ERG was done before and after citicholine and 
there was a significant decrease in the latency and increase in the 
amplitude. 
 After treatment with citicholine, reduced retinocortical time was 
observed as evidenced by the decreased P100 latency and the 
increased N75-P100 amplitude of  VEP. 
 About 17 eyes among the 100 eyes had progressive changes in the 
optic nerve head, visual fields inspite of maximum medical 
therapy and so they were finally taken for partial thickness 
trabeculectomy. 
  
DISCUSSION 
Primary open angle glaucoma (POAG)  is a multifactorial 
syndrome in which progressive optic nerve damage occurs and is related 
to the rise in the intraocular pressure. It is usually bilateral  and 
characterized by IOP>21 mm of Hg and normal appearing open angles. 
There will be associated visual field defects like paracentral scotomas, 
arcuate defects, nasal step defect, tubular fields. Prevalence of  blindness 
from POAG is about 100 per 1,00,000 among people 51-60yrs old. Risk 
factors like age, race, family history, myopia, diabetes mellitus, 
hypertension are associated with POAG. Relative risk of having POAG 
is 5.7 fold in a patient with family history. The optic nerve head damage 
in one eye is significantly associated with damage in the other eye also. 
The patient’s history must be evaluated including past ocular history, 
family history, use of ocular and systemic medications and assessment 
of  visual functions. Visual acuity, IOP, slit lamp examination, optic 
nerve head   examination, gonioscopy, visual field examination  should 
be done. Electrophysiological tests and Psychophysiological tests are 
also helpful for the detection of glaucomatous damage. 
Electrophysiological tests are Electroretinogram and Visual evoked 
potential. Psychophysiological tests are color vision ,spatial and 
temporal contrast sensitivity. 
We are classifying POAG as mild, moderate, severe according to 
the amount of optic disc damage and the visual field abnormalities. Mild 
damage means optic nerve head damage without visual field defects. 
Moderate damage includes visual field abnormalities in one hemifield 
not involving the fixation areas. Severe damage includes visual field 
defects in both the hemifields and involving central 50 of fixation.  
Treatment of  POAG is primarily medical management, but if the 
damage progresses despite maximum medical management, 
trabeculectomy can be done. The  basic principle of treatment is 
identification of target pressure(below which glaucomatous  damage 
will not progress).we have to start with a single drug therapy ,usually a 
beta blocker/prostaglandin  analogue, then patient followed up after 4 
weeks and a fall in IOP of  >4 mm of Hg is significant. If response is 
satisfactory, follow up after 2 months  &  3-4 months thereafter is 
enough. If response is unsatisfactory, another drug should be substituted 
for the initial drug. If  still unsatisfactory, another drug added/combined 
preparation substituted. During the course of the therapy, monitoring 
should be done by assessing the disc changes, field changes, color vision 
and contrast sensitivity. In our study, all the 100 POAG  patients are 
done, the complete  glaucoma evaluation including history, intraocular 
pressure, central corneal thickness, slit lamp examination, fundus 
examination, gonioscopy, visual field examination. All these patients are 
followed up every 6 months to analyse the progression/regression of  
visual functions in POAG. Also other investigations like color vision, 
contrast sensitivity was done for all patients. Visual evoked 
potential(VEP) was done for 30 patients and the neuroprotective role of 
citicholine was assessed using VEP by analysing the cortical responses. 
Electroretinogram was done for 5 patients.  
In the last two decades so many multicentric randomised 
controlled trials were conducted regarding medical therapy in glaucoma. 
But these trials has been conducted in largely Caucasian populations 
with rigid inclusion and exclusion criteria and these may not be directly 
applicable to our community. One such study is the ocular hypertensive 
treatment study(OHTS) which states that early treatment produced about 
a reduction of a 20% reduction in IOP, reduced incidence of  POAG 
participants by 60% at 5yrs from 9.5% in the observation group to 4.4% 
in the medication group. Also this study showed that African Americans 
have a higher prevalence and incidence of POAG and this racial effect 
may be due to thinner CCT and larger cup disc ratios. In our study, after 
2 yrs of follow up, the mean intraocular pressure was very much 
reduced, the optic nerve head with moderate damage progressed to 
severe damage in some patients and the visual field defects also 
progressed to tubular and biarcuate defects in patients with increasing  
cup disc ratio. In patients with central corneal thickness <500µ,there 
was a significant optic nerve head damage and visual field defects. 
Patients presented with RAPD, had defective color vision and contrast 
sensitivity.  
After citicholine, there was a decline in the latency and increase 
in the amplitude in VEP  and  ERG, suggestive of  neuroprotective role 
of citicholine. There  is also a decrease in the retinocortical time. 
According to the early manifest glaucoma treatment 
study(EMGT),early treatment which reduced the IOP  by 25% halved 
the risk of progression of glaucoma and the risk decreased by about 10% 
with each mm reduction  in IOP and thinner CCT  is a risk factor in 
POAG patients . 
In our study, at the end of 2 yrs, those people who had a severe 
glaucomatous damage were done partial thickness trabeculectomy. 
Newly diagnosed POAG patients are better treated by medications than 
by surgery. According to the collaborative initial glaucoma treatment 
study(CIGTS),visual field loss occurred in 10.7% of the medication 
group compared to 13.5% of the surgical group and initial surgery 
resulted in the development of  more cataracts than the initial medical 
treatment(17% Vs 6%). 
Patients with POAG requires follow up every 6 months, but the 
follow up can be according to the severity and progression of the 
disease. In addition to treating the ocular condition, ophthalmologist 
shold educate the patient for adopting a healthy life style and take care 
of the systemic disease also. For primary prevention and early  
detection, screening of the family members is also recommended. It 
should be emphasised that regular eye examinations  and treatment 
throughout life is a must and vision lost through glaucoma cannot be 
restored and the purpose of the therapy is to preserve the already 
existing vision. 
  
CONCLUSION 
 Patients with POAG should be done a thorough history taking 
including the past ocular and the family history and a complete 
glaucoma evaluation including visual acuity, intraocular pressure, 
central corneal thickness, slit lamp examination, optic nerve head 
examination, gonioscopy, visual fields. 
 IOP > 21 mm of Hg, central corneal thickness of  less than 
550µ,cup disc ratio> 0.4,open angles in gonioscopy, visual field 
defects are characteristic of POAG. 
 POAG patients with CCT<550µ are more prone for optic nerve 
head damage progression and also for the progression in the 
visual field defects. 
 After treatment with citicholine, there is a reduced retinocortical 
time as evidenced by VEP and ERG. 
 Purpose of glaucoma treatment is to preserve the vision related 
quality of the patient. 
 Specific goal is to achieve the target IOP and then to treat the 
systemic factors. 
 Patients treated initially with medical therapy had a reduction in 
the intraocular pressure compared to the primary trabeculectomy. 
 Patients with POAG should be followed up every 6 months, but 
may vary according to the severity of the disease. 
 For primary prevention and detection, periodical checkup of 
family members is indicated. 
 Education of the patient is necessary for adopting a healthy life 
style and measures like asking the patient to stop smoking, regular 
exercise, meditation to decrease the stress associated with disease 
will improve the quality of life in these patients. 
FUTURE SCOPE 
Citicholine is significant in improving the retinal and cortical 
responses in glaucoma patients. So it can be used in the medical 
management of glaucoma as an adjuvant to antiglaucoma therapy. 
VEP and ERG can be used as a standard tests to assess the 
progression of primary open angle glaucoma. 
The quality of life in POAG on long term medical therapy can be  
 
assessed depending upon the visual function tests. 
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PROFORMA FOR THE ANALYSIS OF VISUAL FUNCTIONS  
IN PRIMARY OPEN ANGLE GLAUCOMA 
Name: 
Age:          Sex:                                                         
Address:                                                    
                         Phone No: 
 
Glaucoma No. 
Presenting Complaint: 
Defective Vision 
Total Loss Of Vision 
Pain,Redness,Coloured Haloes 
Headache 
Frequent Change Of Glasses 
Family History Of Glaucoma 
H/O Diabetes Mellitus/Hypertensive/Bronchial Asthmatic/Ischemic 
Heart Disease 
H/O  Topical Medication 
H/O  Trauma 
H/O  Cataract/Glaucoma Surgery/LASER PI 
Ocular Examination:   
RE     LE 
Visual Acuity 
Intraocular Pressure 
(Applanation Tonometry) 
CCT 
 
Slit Lamp Examination 
Lid 
Conjunctiva 
Cornea 
Anterior Chamber 
Iris 
Pupil 
Lens 
 
Fundus Examination 
Media 
Disc 
CD Ratio 
Vessels 
N/B/PPA/LDS 
Macula 
 GONIOSCOPY 
Automated Perimetry 
Reliability 
Defects 
COLOR VISION 
CONTRAST SENSITIVITY 
 
VEP 
P100 LATENCY 
AMPLITUDE 
 
ERG 
P50 LATENCY 
AMPLITUDE 
 
DIAGNOSIS 
MANAGEMENT 
 
  
Follow Up 
Date: 
Drugs: 
Compliance: 
Visual Acuity: 
IOP: 
Anterior Segment: 
Fundus Examination: 
Color Vision: 
Contrast Sensitivity: 
Visual Fields: 
VEP: 
  
LIST OF SURGERIES PERFORMED 
S.NO. NAME AGE/SEX DIAGNOSIS SURGERY 
1. Sethuraman 72/m POAG LE Trab 
2. Anandamary 60/f POAG LE Trab 
3. Logammbal 67/f POAG RE Trab 
4. Pandikani 25/m POAG RE Trab 
5. Chanchal 26/m POAG RE Trab 
6. Moorthy 34/m POAG RE Trab 
7. Jamuna  48/f POAG RE Trab 
8. Arumugam 50/m POAG LE Trab 
9. Chinnakulandhai 60/m POAG+IMC LE Trab+SICS 
10. Thangavel 64/m POAG LE Trab 
11. Rani 35/f POAG LE Trab 
12. Vijayan 55/m POAG LE Trab 
13. Dawood Basha 65/m POAG+MC RE Trab+SICS 
14. Manian 76/m POAG RE Trab 
15. Karupayee 62/f POAG+IMC LE Trab+SICS 
16. Samrajiyam 75/m POAG+MC RE Trab+ECCE 
17. Shanmugam 60/m POAG RE Trab 
 
  
 
 
 
 
 
 
MASTER CHART 
     IOP       CCT        AS       CV        CS       ONH
1 rajagopal 45 m chennai 0 0 RE 6/9 PH 6/6 M 21 598 N N N 0.4
LE 5/60 PH 6/6P MA 22 596 N N N 0.7
2 padmini 62 F chennai 1 0 RE 6/36 PH 6/6P MA 24 570 N N N 0.6
LE 6/24 PH 6/6P A 22 572 N N N 0.7
3 sethuraman 72 m chennai 0 0 RE 6/9P PH 6/6 22 550 N N N 0.3
LE 6/18 PH 6/9 21 551 N N N 0.6
4 ramadoss 61 m chennai 0 0 RE 6/18 PH6/6 M 23 540 N N N 0.6
LE 6/9 PH 6/6 M 24 530 N N N 0.5
5 anandhamary 60 f chennai 0 0 RE 6/24 PH 6/18 20 496 N N N 0.8
LE 3/60 PH 6/60 22 518 RAPD D D 0.8
6 logambal 67 f chennai 0 0 RE 6/18 PH 6/9 22 510 LC N N 0.8
LE 6/24 PH 6/12 21 514 LC N N 0.7
7 karupayee 62 f kadampathu 1,2 0 RE 5/60 PH6/36 24 550 IMC N N 0.8
LE 3/60NIP 21 552 IMC N N 0.9
8 kamatchi 83 f chennai 2 0 RE 6/18 PH 6/6 M 21 519 N N N 0.8
LE 6/36 PH 6/6P M 22 520 N N N 0.8
9 saroja 55 f chennai 1,2,3 0 RE 3/60NIP 21 510 IMC N N 0.6
LE 6/12P PH 6/6 21 512 LC N N 0.5
10 pandikani 25 m chennai 0 0 RE 6/60 PH 6/36 M 40 560 RAPD+ D D 0.9
LE 6/60 PH 6/18 M 40 560 N N N 0.8
11 hart 70 m chennai 0 0 RE HM 21 504 NS ND ND 0.9
LE 6/9 PH 6/6 21 502 N N N 0.4
12 gnanam 56 f chennai 1 0 RE 6/9 PH  6/6 H 21 585 N N N 0.5
LE 6/9 PH  6/6 H 24 590 N N N 0.9
13 subramaniam 58 m chennai 0 0 RE 6/9 PH 6/6 HP 22 530 N N N 0.7
LE 6/18 PH 6/6 HP 22 534 N N N 0.5
14 chanchal 26 m calcutta 0 0 RE 6/60 PG6/18 M 23 580 RAPD+ D D 0.9
LE 6/36 PG 6/9P M 22 570 N N N 0.5
15 kumar 50 m chennai 0 0 RE 6/9 PH 6/6P N 36 449 N N N 0.7
LE 6/18 PH 6/12 N 20 442 N N N 0.4
16 nagammal 30 f chennai 0 0 RE NO PL 48 532 RAPD,PSCC D D 0.9
LE 4/60NIP 46 527 PSCC N N 0.6
17 moorthy 34 m chennai 0 0 RE 6/24 PH 6/12 HP 42 540 N N N 0.9
LE 6/60NIP 40 550 N N N 0.9
18 jamuna 48 f chennai 2 0 RE 6/60 PH 6/24 HP 30 505 N N N 0.9
LE 6/60 PH 6/24 HP 32 505 N N N 0.8
19 santhanam 70 m chennai 0 0 RE 6/12P PH 6/6 21 520 IMC N N 0.4
LE 6/12P PH 6/6 28 516 IMC N N 0.4
20 muthu 57 m chennai 2 0 RE 6/9 PH 6/6P M 34 536 LC N N 0.9
LE 6/9 PH 6/6P M 28 534 LC N N 0.7
21 perumal 65 m chennai 0 0 RE 6/18 PH 6/12 42 504 PCIOL N N 0.8
LE 6/36 PH 6/6P 46 505 PCIOL N N 0.9
22 arumugam 50 m arakonam 0 0 RE 6/18 PH 6/12 21 535 RAPD+ D D 0.8
LE PL+ 34 540 RAPD+ ND ND 0.9
23 subramani 54 m chennai 0 1 RE 6/24 PH 6/9 M 24 524 LC N N 0.6
LE 6/12 PH 6/6 M 30 527 LC N N 0.5
24 chinnakannu 60 m ariyalur 0 0 RE CFCF 28 480 PCIOL ND ND 0.7
LE 6/36 PH 6/6P 21 470 PCIOL N N 0.7
25 shalini 28 f chennai 0 0 RE 6/60 PH 6/6 M 24 602 N N N 0.6
LE 6/6P M 22 584 N N N 0.6
26 kothandam 75 m kumbakonam 1,2 0 RE 6/18 PH 6/9 22 555 IMC N N 0.4
LE 6/18 PH 6/9 22 545 IMC N N 0.5
27 gomas 61 m chennai 0 0 RE 6/24 PH 6/9P HP 22 540 LC N N 0.6
LE 6/24 PH 6/9P HP 38 536 LC N N 0.7
28 lakshmi 49 f gumidipoondi 0 0 RE NO PL 58 485 RAPD+ ND ND 0.9
LE 6/12 PH 6/6 20 478 PCIOL N N 0.3
29 muthusamy 59 m chennai 2 1 RE 6/18 PH 6/9 22 528 IMC N N 0.6
LE 6/18 PH 6/9 22 524 IMC N N 0.5
30 sumathy 40 f chennai 3 0 RE 6/6P M 22 510 N N N 0.5
LE 6/6P M 24 512 N N N 0.7
31 chinnakulandhai  60 f pollur 0 0 RE 2/60NIP 24 532 IMC D D 0.9
LE CFCF 34 534 IMC ND ND 0.9
32 krishna 69 m chennai 2 0 RE CFCF 36 580 RAPD+ ND ND 0.8
LE 6/36 PH6/24P 26 591 N N N 0.3
33 daniel 59 m chennai 2 0 RE 6/24P PH6/18 36 475 N N N 0.5
LE 6/24 PH 6/12P 40 500 N N N 0.4
34 kondammal 52 f chennai 0 0 RE 6/24 PH 6/12 N 21 490 N N N 0.5
LE 6/9P PH 6/6 N 22 496 N N N 0.5
35 amal raj 55 m chennai 0 0 RE 6/36 PH 6/6P M 24 480 N N N 0.4
LE 6/9 PH 6/6 M 24 485 N N N 0.4
36 nagammal 50 f thiruvallur 0 0 RE 4/60NIP 30 510 N N N 0.6
LE 4/60NIP 22 514 N N N 0.7
37 thangavel 64 f chennai 0 0 RE 6/24 PH 6/12 28 523 IMC N N 0.5
LE 6/12 PH 6/9 24 526 PCIOL N N 0.8
38 senthil 55 m chennai 0 0 RE 6/18 PH 6/12 M 56 555 N N N 0.8
LE  6/6P PH 6/6 M 34 552 N N N 0.3
39 poongavanam 55 m chennai 0 0 RE 6/24P PH6/18 24 546 N N N 0.7
LE 6/36 PH 6/6P 22 540 N N N 0.8
40 sw aminathan 60 m chennai 0 0 RE 6/36 PH 6/18 42 534 IMC N N 0.6
LE 6/18 PH 6/9P 22 532 N N N 0.8
41 satishkumar 31 m chennai 0 0 RE 6/36 PH 6/6P M 24 580 N N N 0.7
LE 6/18P PH 6/6 M 26 584 N N N 0.7
42 manoharan 50 m chennai 0 0 RE 6/60 PH 6/12 24 541 N N N 0.5
LE 6/60 PH 6/12 22 543 N N N 0.8
43 rani 35 f chennai 0 0 RE HM+ 22 490 NS ND ND NO VIEW
LE HM+ 22 510 RAPD+ ND ND 0.9
44 ragunathan 74 m chennai 0 0 RE 1/60 PH 6/18P 22 567 NS N N 0.6
LE 1/60 PH 6/18P 21 569 NS N N 0.8
45 selvi 33 f chennai 3 0 RE 6/24 PH 6/6P M 32 564 N N N 0.6
LE 1/60 PH 6/18P M 40 573 N N N 0.9
46 vijayan 55 m chennai 0 0 RE 6/18 PH 6/6 M 22 514 N N N 0.7
LE 6/36 PH 6/6P M 22 524 RAPD+ D D 0.9
47 sundar 64 m chennai 0 0 RE NO PL 58 523 LEUCOMA ND ND NO VIEW N
 PLACE   SEX     AGE   NAME
 SI 
NO. RRVAEYEFHSD
during f irst visit
 KEY TO MASTER CHART 
RE - RIGHT EYE, 
LE - LEFT EYE 
PH - PIN HOLE 
VA - VISUAL ACUITY 
FH - FAMILY HISTORY, 
  1-YES, 0-NO 
SD - SYSTEMIC DISEASE 
1. DIABETES MELLITUS, 
2. HYPERTENSION, 
3. BRONCHIAL ASTHMA, 
4. ISCHEMIC HEART DISEASE. 
RR - RETINOSCOPY 
M - MYOPIA 
HP - HYPERMETROPIA 
MA - MYOPIC ASTIGMATISM 
IOP - INTRAOCULAR PRESSURE 
CCT - CENTRAL CORNEAL THICKNESS 
AS - ANTERIOR SEGMENT 
RAPD - RELATIVE AFFERENT PUPILLARY DEFECT 
N - NORMAL 
LC - LENS CHANGES 
IMC - IMMATURE CATARACT 
MC - MATURE CATARACT 
PSCC - POSTERIOR SUBCAPSULAR CATARACT 
CV - COLOR VISION 
CS - CONTRAST SENSITIVITY 
ND - NOT DONE 
D - DEFECTIVE 
PCIOL - POSTERIOR CHAMBER INTRAOCULAR LENS 
ONH - OPTIC NERVE HEAD 
CDR - CUP DISC RATIO 
GOA - GLAUCOMATOUS OPTIC ATROPHY 
AP - AUTOMATED PERIMETRY 
1. INFERIOR AND SUPERIOR ARCUATE DEFECTS 
2. INFERIOR ARCUATE DEFECT 
3. SUPERIOR ARCUATE DEFECT 
4. TUBULAR DEFECT 
5. PARACENTRAL DEFECT 
6. FIXATION DEFECT 
7. NORMAL 
8. NASAL STEP DEFECT 
RX - TREATMENT 
T - TIMOLOL 
BR - BRIMONIDINE 
BMT - BIMATOPROST 
L - LATANOPROST 
B - BETOXALOL 
D - DORZOLAMIDE 
DI - DIAMOX 
G - GLYCEROL 
M - MANNITOL 
CIT - CITICOLINE 
TRAB - TRABECULECTOMY 
SICS - SMALL INCISION CATARACT SURGERY 
ECCE - EXTRACAPSULAR CATARACT SURGERY 
 
 
 
 
 
